neuromyelitis optica spectrum disorder
Neurology · 2020–2024
3decisions
2medicines
3carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ravulizumab Treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are aquaporin-4 (AQP4) positive who have experienced a recent relapse… | Nov 2024 | Recommended with restriction | 3 individuals |
| eculizumab Treatment of patients with neuromyelitis optica spectrum disorder (NMOSD) who are aquaporin-4 positive (AQP4+) with an Expanded Disability Status Scale (EDSS)… | Nov 2021 | Not recommended | input received MS Australia |
| eculizumab Treatment of patients with neuromyelitis optica spectrum disorder (NMOSD) who are aquaporin-4 (AQP4) positive and who have either frequent relapses or a prior… | Nov 2020 | Not recommended | input received MS Australia · MS Research Australia |
Who spoke
MS Australia · MS Research Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.